Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending April 28, 2006. The report details a specific corporate action regarding the repurchase of the company's own ordinary shares.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. It focuses exclusively on share repurchase activity.
- Shares Purchased: 640,000 ordinary shares of 25 pence each.
- Purchase Price: 1,562.6105 pence per share.
- Treasury Shares Held: 157,834,678 shares following the transaction.
- Shares in Issue: 5,817,109,585 shares (excluding Treasury shares).
Material Changes
The material change reported is the reduction of outstanding shares through a buyback executed on April 28, 2006. This action was taken under authority granted by shareholders at the Annual General Meeting on May 25, 2005. The filing does not provide comparative data against prior periods for financial performance.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or contingencies regarding future business operations. It explicitly states that the announcement does not constitute an offer or solicitation to purchase securities.
Investor Verification Checklist
- Verify the total cost of the 640,000 shares purchased at the stated price of 1,562.6105 pence.
- Confirm the updated total number of shares in issue (5,817,109,585) against the company's latest capitalization table.
- Review the remaining authorization for share buybacks under the mandate approved on May 25, 2005.
- Check subsequent filings for the impact of this treasury share holding on earnings per share calculations.